{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:11:38Z","timestamp":1794370298901,"version":"4.9.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["PS2023-0009"],"award-info":[{"award-number":["PS2023-0009"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008084","name":"Neurof\u00f6rbundet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-985193"],"award-info":[{"award-number":["SLS-985193"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003514","name":"Kommunfullm\u00e4ktige, Stockholms Stad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>There is scientific evidence for ongoing neurodegeneration and alpha-synuclein pathology involving the peripheral nervous system in Parkinson\u2019s disease (PD) and multiple system atrophy (MSA). We explored putative disease-mirroring properties of cutaneous nerve fibers in patients with PD (<jats:italic>n<\/jats:italic>\u2009=\u200920), MSA (<jats:italic>n<\/jats:italic>\u2009=\u200912), four-repeat tauopathies (<jats:italic>n<\/jats:italic>\u2009=\u200911), and controls (<jats:italic>n<\/jats:italic>\u2009=\u200920). Assessments included clinical rating scales, blood sampling, sudomotor testing, skin punch biopsies from the neck and leg, and 1-year follow-up. Skin alpha-synuclein seeding amplification assay (SAA) and determination of intraepidermal nerve fiber density (IENFD) were performed. Reduced electrochemical skin conductance was evident in MSA, associated with clinical rating scores. Cervical skin SAA (PD vs controls) achieved a 100% sensitivity and 70% specificity for detecting PD. We found no difference in baseline IENFD, nor in 1-year changes, in patients relative to controls. Baseline IENFD, plasma neurofilament light, and SAA kinetics associated with 1-year clinical disease progression in MSA. Skin may harbor promising prognostic properties in MSA.<\/jats:p>","DOI":"10.1038\/s41531-025-01030-y","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T02:06:42Z","timestamp":1749953202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cutaneous nerve fiber pathology and function in Parkinson\u2019s disease and atypical parkinsonism \u2013 a cohort study"],"prefix":"10.1038","volume":"11","author":[{"given":"Mattias","family":"Andr\u00e9asson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Paslawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Juhl","family":"Terkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Samuelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1ll","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"key":"1030_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1212\/WNL.0000000000004274","volume":"89","author":"M Nolano","year":"2017","unstructured":"Nolano, M. et al. Loss of cutaneous large and small fibers in naive and L-DOPA-treated PD patients. Neurology 89, 776\u2013784 (2017).","journal-title":"Neurology"},{"key":"1030_CR2","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/brain\/awn102","volume":"131","author":"M Nolano","year":"2008","unstructured":"Nolano, M. et al. Sensory deficit in Parkinson\u2019s disease: evidence of a cutaneous denervation. Brain 131, 1903\u20131911 (2008).","journal-title":"Brain"},{"key":"1030_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41531-021-00262-y","volume":"7","author":"E Vacchi","year":"2021","unstructured":"Vacchi, E. et al. Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson\u2019s disease. NPJ Parkinson's Dis. 7, 119 (2021).","journal-title":"NPJ Parkinson's Dis."},{"key":"1030_CR4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/acn3.669","volume":"5","author":"G Melli","year":"2018","unstructured":"Melli, G. et al. Cervical skin denervation associates with alpha-synuclein aggregates in Parkinson disease. Ann. Clin. Transl. Neurol. 5, 1394\u20131407 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1030_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-014-1284-0","volume":"128","author":"K Doppler","year":"2014","unstructured":"Doppler, K. et al. Cutaneous neuropathy in Parkinson\u2019s disease: a window into brain pathology. Acta Neuropathol. 128, 99\u2013109 (2014).","journal-title":"Acta Neuropathol."},{"key":"1030_CR6","doi-asserted-by":"publisher","unstructured":"Wang, Z. et al. Skin alpha-synuclein aggregation seeding activity as a novel biomarker for Parkinson's disease. JAMA Neurol, https:\/\/doi.org\/10.1001\/jamaneurol.2020.3311 (2020).","DOI":"10.1001\/jamaneurol.2020.3311"},{"key":"1030_CR7","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"1030_CR8","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons, C. H. et al. Skin biopsy detection of phosphorylated alpha-synuclein in patients with synucleinopathies. JAMA 331, 1298\u20131306 (2024).","journal-title":"JAMA"},{"key":"1030_CR9","doi-asserted-by":"publisher","first-page":"e1282","DOI":"10.1212\/WNL.0000000000013300","volume":"98","author":"V Provitera","year":"2022","unstructured":"Provitera, V. et al. Postganglionic sudomotor assessment in early stage of multiple system atrophy and Parkinson's disease: a morpho-functional study. Neurology 98, e1282\u2013e1291 (2022).","journal-title":"Neurology"},{"key":"1030_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10286-017-0467-x","volume":"29","author":"P Novak","year":"2019","unstructured":"Novak, P. Electrochemical skin conductance: a systematic review. Clin. Auton. Res. 29, 17\u201329 (2019).","journal-title":"Clin. Auton. Res."},{"key":"1030_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.parkreldis.2019.07.034","volume":"66","author":"C Popescu","year":"2019","unstructured":"Popescu, C. Small fiber neuropathy in Parkinson\u2019s disease explored by the sudoscan. Park. Relat. Disord. 66, 261\u2013263 (2019).","journal-title":"Park. Relat. Disord."},{"key":"1030_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.sleep.2018.08.023","volume":"52","author":"C Rocchi","year":"2018","unstructured":"Rocchi, C. et al. Daytime autonomic activity in idiopathic rapid eye movement sleep behavior disorder: a preliminary study. Sleep. Med. 52, 163\u2013167 (2018).","journal-title":"Sleep. Med."},{"key":"1030_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neucli.2017.11.003","volume":"48","author":"A Pavy-LeTraon","year":"2018","unstructured":"Pavy-LeTraon, A. et al. Combined cardiovascular and sweating autonomic testing to differentiate multiple system atrophy from Parkinson\u2019s disease. Neurophysiol. Clin. 48, 103\u2013110 (2018).","journal-title":"Neurophysiol. Clin."},{"key":"1030_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neucli.2022.102840","volume":"53","author":"J Idiaquez","year":"2023","unstructured":"Idiaquez, J., Casar, J. C., Fadic, R. & Iturriaga, R. Sympathetic and electrochemical skin responses in the assessment of sudomotor function: a comparative study. Neurophysiol. Clin. 53, 102840 (2023).","journal-title":"Neurophysiol. Clin."},{"key":"1030_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2021.102773","volume":"231","author":"BS Gagaouzova","year":"2021","unstructured":"Gagaouzova, B. S. et al. Can novel non-invasive autonomic tests help discriminate between pure autonomic failure and multiple system atrophy? Auton. Neurosci. 231, 102773 (2021).","journal-title":"Auton. Neurosci."},{"key":"1030_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/mds.26864","volume":"32","author":"EA Coon","year":"2017","unstructured":"Coon, E. A. et al. Anhidrosis in multiple system atrophy involves pre- and postganglionic sudomotor dysfunction. Mov. Disord. 32, 397\u2013404 (2017).","journal-title":"Mov. Disord."},{"key":"1030_CR17","doi-asserted-by":"publisher","first-page":"e1529","DOI":"10.1212\/WNL.0000000000206772","volume":"100","author":"C Gibbons","year":"2023","unstructured":"Gibbons, C. et al. Cutaneous alpha-synuclein signatures in patients with multiple system atrophy and Parkinson disease. Neurology 100, e1529\u2013e1539 (2023).","journal-title":"Neurology"},{"key":"1030_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/WNL.0000000000002919","volume":"87","author":"CH Gibbons","year":"2016","unstructured":"Gibbons, C. H., Garcia, J., Wang, N., Shih, L. C. & Freeman, R. The diagnostic discrimination of cutaneous alpha-synuclein deposition in Parkinson disease. Neurology 87, 505\u2013512 (2016).","journal-title":"Neurology"},{"key":"1030_CR19","doi-asserted-by":"publisher","first-page":"e2513","DOI":"10.1212\/WNL.0000000000011935","volume":"96","author":"V Donadio","year":"2021","unstructured":"Donadio, V. et al. In vivo diagnosis of synucleinopathies: a comparative study of skin biopsy and RT-QuIC. Neurology 96, e2513\u2013e2524 (2021).","journal-title":"Neurology"},{"key":"1030_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41531-021-00242-2","volume":"7","author":"A Kuzkina","year":"2021","unstructured":"Kuzkina, A. et al. Diagnostic value of skin RT-QuIC in Parkinson\u2019s disease: a two-laboratory study. NPJ Parkinson's Dis. 7, 99 (2021).","journal-title":"NPJ Parkinson's Dis."},{"key":"1030_CR21","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/mds.28651","volume":"36","author":"A Mammana","year":"2021","unstructured":"Mammana, A. et al. RT-QuIC detection of pathological alpha-synuclein in skin punches of patients with lewy body disease. Mov. Disord. 36, 2173\u20132177 (2021).","journal-title":"Mov. Disord."},{"key":"1030_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/mds.28011","volume":"35","author":"M Jecmenica Lukic","year":"2020","unstructured":"Jecmenica Lukic, M. et al. Copathology in progressive supranuclear palsy: does it matter? Mov. Disord. 35, 984\u2013993 (2020).","journal-title":"Mov. Disord."},{"key":"1030_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00401-018-1876-1","volume":"136","author":"M Nolano","year":"2018","unstructured":"Nolano, M. et al. Small fiber pathology parallels disease progression in Parkinson's disease: a longitudinal study. Acta Neuropathol. 136, 501\u2013503 (2018).","journal-title":"Acta Neuropathol."},{"key":"1030_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/JPD-181357","volume":"8","author":"A Al-Qassabi","year":"2018","unstructured":"Al-Qassabi, A., Pelletier, A., Fereshtehnejad, S. M. & Postuma, R. B. Autonomic sweat responses in REM sleep behavior disorder and parkinsonism. J. Parkinson's Dis. 8, 463\u2013468 (2018).","journal-title":"J. Parkinson's Dis."},{"key":"1030_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0667-3","volume":"16","author":"DF de Araujo","year":"2016","unstructured":"de Araujo, D. F. et al. Small (autonomic) and large fiber neuropathy in Parkinson's disease and parkinsonism. BMC Neurol. 16, 139 (2016).","journal-title":"BMC Neurol."},{"key":"1030_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz, M. et al. Discriminating alpha-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578, 273\u2013277 (2020).","journal-title":"Nature"},{"key":"1030_CR27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/mds.25486","volume":"28","author":"KM Doherty","year":"2013","unstructured":"Doherty, K. M. & Hardy, J. Parkin disease and the Lewy body conundrum. Mov. Disord. 28, 702\u2013704 (2013).","journal-title":"Mov. Disord."},{"key":"1030_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.parkreldis.2019.07.032","volume":"66","author":"A Puschmann","year":"2019","unstructured":"Puschmann, A. et al. Low prevalence of known pathogenic mutations in dominant PD genes: a Swedish multicenter study. Park. Relat. Disord. 66, 158\u2013165 (2019).","journal-title":"Park. Relat. Disord."},{"key":"1030_CR29","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"1030_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670\u2013676 (2008).","journal-title":"Neurology"},{"key":"1030_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord."},{"key":"1030_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496\u2013503 (2013).","journal-title":"Neurology"},{"key":"1030_CR33","first-page":"115:E117ER","volume":"115","author":"A Danielsson","year":"2018","unstructured":"Danielsson, A. Alkoholberoende ett f\u00f6r\u00e4nderligt tillst\u00e5ende av varierande grad. L\u00e4kartidningen 115, 115:E117ER (2018).","journal-title":"L\u00e4kartidningen"},{"key":"1030_CR34","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"1030_CR35","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/mds.20255","volume":"19","author":"GK Wenning","year":"2004","unstructured":"Wenning, G. K. et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov. Disord. 19, 1391\u20131402 (2004).","journal-title":"Mov. Disord."},{"key":"1030_CR36","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/mds.27964","volume":"35","author":"I Piot","year":"2020","unstructured":"Piot, I. et al. The Progressive Supranuclear Palsy Clinical Deficits Scale. Mov. Disord. 35, 650\u2013661 (2020).","journal-title":"Mov. Disord."},{"key":"1030_CR37","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz, C. G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. Disord. 19, 1020\u20131028 (2004).","journal-title":"Mov. Disord."},{"key":"1030_CR38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427\u2013442 (1967).","journal-title":"Neurology"},{"key":"1030_CR39","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","volume":"38","author":"ST Jost","year":"2023","unstructured":"Jost, S. T. et al. Levodopa dose equivalency in Parkinson\u2019s disease: updated systematic review and proposals. Mov. Disord. 38, 1236\u20131252 (2023).","journal-title":"Mov. Disord."},{"key":"1030_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1529-8027.2008.00180.x","volume":"13","author":"JR Singleton","year":"2008","unstructured":"Singleton, J. R. et al. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J. Peripher Nerv. Syst. 13, 218\u2013227 (2008).","journal-title":"J. Peripher Nerv. Syst."},{"key":"1030_CR41","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/mds.20153","volume":"19","author":"M Visser","year":"2004","unstructured":"Visser, M., Marinus, J., Stiggelbout, A. M. & Van Hilten, J. J. Assessment of autonomic dysfunction in Parkinson\u2019s disease: the SCOPA-AUT. Mov. Disord. 19, 1306\u20131312 (2004).","journal-title":"Mov. Disord."},{"key":"1030_CR42","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3233\/JPD-191697","volume":"9","author":"M Jeziorska","year":"2019","unstructured":"Jeziorska, M. et al. Small fibre neuropathy in Parkinson\u2019s disease: comparison of skin biopsies from the more affected and less affected sides. J. Parkinson's Dis. 9, 761\u2013765 (2019).","journal-title":"J. Parkinson's Dis."},{"key":"1030_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1529-8027.2010.00271.x","volume":"15","author":"G Lauria","year":"2010","unstructured":"Lauria, G. et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J. Peripher Nerv. Syst. 15, 202\u2013207 (2010).","journal-title":"J. Peripher Nerv. Syst."},{"key":"1030_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.sjpain.2015.08.007","volume":"10","author":"P Karlsson","year":"2016","unstructured":"Karlsson, P., Haroutounian, S., Polydefkis, M., Nyengaard, J. R. & Jensen, T. S. Structural and functional characterization of nerve fibres in polyneuropathy and healthy subjects. Scand. J. Pain. 10, 28\u201335 (2016).","journal-title":"Scand. J. Pain."},{"key":"1030_CR45","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/NEN.0b013e318284e849","volume":"72","author":"P Karlsson","year":"2013","unstructured":"Karlsson, P., Moller, A. T., Jensen, T. S. & Nyengaard, J. R. Epidermal nerve fiber length density estimation using global spatial sampling in healthy subjects and neuropathy patients. J. Neuropathol. Exp. Neurol. 72, 186\u2013193 (2013).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1030_CR46","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.neucli.2022.08.003","volume":"52","author":"R Ozturk","year":"2022","unstructured":"Ozturk, R. et al. Stereological and electrophysiological evaluation of autonomic involvement in amyotrophic lateral sclerosis. Neurophysiol. Clin. 52, 446\u2013458 (2022).","journal-title":"Neurophysiol. Clin."},{"key":"1030_CR47","doi-asserted-by":"publisher","first-page":"15226","DOI":"10.1073\/pnas.1821409116","volume":"116","author":"W Paslawski","year":"2019","unstructured":"Paslawski, W. et al. alpha-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson\u2019s disease patients. Proc. Natl. Acad. Sci. USA 116, 15226\u201315235 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1030_CR48","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","volume":"18","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio, L., Pritzkow, S., Shahnawaz, M., Farris, C. M. & Soto, C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat. Protoc. 18, 1179\u20131196 (2023).","journal-title":"Nat. Protoc."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01030-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01030-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01030-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T03:26:45Z","timestamp":1749958005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01030-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01030-y","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,15]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A. declares no competing interest. W.P. has received funding from Parkinsonfonden Sweden. A.J.T. is funded by Novo Nordisk Borregaard Clinical Ascending grant (NNF23OC0082689) and has received honorarium from AstraZeneca UK limited, Novo Nordisk Denmark A\/S, Alnylam Pharmaceuticals and Sanofi A\/S.K.S. declares no competing interest. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union\u2019s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer\u2019s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union\u2019s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer\u2019s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen R\u00f6nstr\u00f6ms Stiftelse, Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor, Hj\u00e4rnfonden, Sweden (#FO2022-0270), the European Union\u2019s Horizon 2020 research and innovation programme under the Marie Sk\u0142odowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme \u2013 Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). H.Z. has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hj\u00e4rnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer\u2019s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer\u2019s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen R\u00f6nstr\u00f6ms Stiftelse, Stockholm, Sweden. KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. P.K. declares no competing interest. P.S. has received honorarium for lectures or scientific board consultations from Lundbeck, AstraZeneca, Bial, and AbbVie.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}